Indivior Pharmaceuticals Inc (INDV) — Financial statements
Income statement, balance sheet, and cash flow for Indivior Pharmaceuticals Inc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,239↑4.3% | 1,188↑8.7% | 1,093↑21.3% | 901↑13.9% | 791 | |
| Cost of Revenue | 246↑6.5% | 231↑32.8% | 174↑15.2% | 151↑18.9% | 127 | |
| Gross Profit | 993↑3.8% | 957↑4.1% | 919↑22.5% | 750↑13.0% | 664 | |
| Operating Expenses | ||||||
| R&D Expenses | 97↓9.3% | 107↓7.8% | 116↑56.8% | 74↑42.3% | 52 | |
| General & Administrative Expenses | 319↓12.1% | 363↑9.0% | 333↑32.7% | 251↑5.0% | 239 | |
| Selling & Marketing Expenses | 315↑23.5% | 255↑8.1% | 236↑8.3% | 218↑13.5% | 192 | |
| SG&A Expenses | 634↑2.6% | 618↑8.6% | 569↑21.3% | 469↑8.8% | 431 | |
| Other Expenses | -3↓101.5% | 200↓48.7% | 390↑35.4% | 288↑1000.0% | -32 | |
| Operating Expenses | 728↓21.3% | 925↓14.0% | 1,075↑29.4% | 831↑84.3% | 451 | |
| Total Costs & Expenses | 974↓15.7% | 1,156↓7.4% | 1,249↑27.2% | 982↑69.9% | 578 | |
| Operating Results | ||||||
| Operating Income | 265↑728.1% | 32↑120.5% | -156↓92.6% | -81↓138.0% | 213 | |
| Depreciation & Amortization | 20↓31.0% | 29↑93.3% | 15↓6.3% | 16↓27.3% | 22 | |
| EBITDA | 304↑261.9% | 84↑184.8% | -99↓115.2% | -46↓119.3% | 238 | |
| EBIT | 284↑416.4% | 55↑148.2% | -114↓83.9% | -62↓128.7% | 216 | |
| Interest & Other Income | ||||||
| Net Interest Income | -23↓27.8% | -18↓325.0% | 8↑180.0% | -10↑54.5% | -22 | |
| Interest Income | 22↓4.3% | 23↓46.5% | 43↑126.3% | 19↑375.0% | 4 | |
| Interest Expense | 45↑9.8% | 41↑17.1% | 35↑20.7% | 29↑11.5% | 26 | |
| Non-Operating Income | -19↑17.4% | -23↑45.2% | -42↓121.1% | -19↓533.3% | -3 | |
| Other Income / Expenses | -26↓44.4% | -18↓357.1% | 7↑187.5% | -8↑65.2% | -23 | |
| Income Before Tax | 239↑1607.1% | 14↑109.4% | -149↓67.4% | -89↓146.8% | 190 | |
| Income Tax Expense | 29↑163.6% | 11↑155.0% | -20↑54.5% | -44↓193.3% | -15 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 210↑6900.0% | 3↑102.3% | -129↓186.7% | -45↓122.0% | 205 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 210↑10400.0% | 2↑101.6% | -129↓193.2% | -44↓121.5% | 205 | |
| Bottom-Line Net Income | 210↑10400.0% | 2↑101.6% | -129↓193.2% | -44↓121.5% | 205 | |
| EPS (Basic) | 1.68↑11025.8% | 0.02↑3.4% | 0.01↑103.9% | -0.37↓126.8% | 1.38 | |
| EPS (Diluted) | 1.64↑10833.3% | 0.02↑6.4% | 0.01↑103.8% | -0.37↓128.2% | 1.31 | |
| Weighted Average Shares | 125↓5.3% | 132↓3.9% | 137↓1.2% | 139↓4.6% | 146 | |
| Weighted Average Diluted Shares | 128↓3.8% | 133↓6.2% | 142↑2.0% | 139↓9.9% | 154 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.